295 related articles for article (PubMed ID: 25341011)
41. Discovery heralds new approach to the treatment of cystic fibrosis.
Lowe JA
J Med Chem; 2014 Dec; 57(23):9774-5. PubMed ID: 25384240
[No Abstract] [Full Text] [Related]
42. Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P; García-Foncillas J; Salazar R; Pérez-Segura P; García-Carbonero R; Musulén-Palet E; Cuatrecasas M; Landolfi S; Ramón Y Cajal S; Navarro S; ;
Clin Transl Oncol; 2015 Apr; 17(4):264-73. PubMed ID: 25373533
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA dysregulation as a prognostic biomarker in colorectal cancer.
Dong Y; Yu J; Ng SS
Cancer Manag Res; 2014; 6():405-22. PubMed ID: 25342918
[TBL] [Abstract][Full Text] [Related]
44. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers.
Zugazagoitia J; Pérez-Segura P; Manzano A; Blanco I; Vega A; Custodio A; Teulé A; Fachal L; Martínez B; González-Sarmiento R; Cruz-Hernández JJ; Chirivella I; Garcés V; Garre P; Romero A; Caldés T; Díaz-Rubio E; de la Hoya M
Breast Cancer Res Treat; 2014 Nov; 148(2):415-21. PubMed ID: 25342642
[TBL] [Abstract][Full Text] [Related]
45. Metastatic colorectal cancer: current state and future directions.
Fakih MG
J Clin Oncol; 2015 Jun; 33(16):1809-24. PubMed ID: 25918280
[TBL] [Abstract][Full Text] [Related]
46. Primary tumor location as a prognostic factor in metastatic colorectal cancer.
Loupakis F; Yang D; Yau L; Feng S; Cremolini C; Zhang W; Maus MK; Antoniotti C; Langer C; Scherer SJ; Müller T; Hurwitz HI; Saltz L; Falcone A; Lenz HJ
J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25713148
[TBL] [Abstract][Full Text] [Related]
47. Mechanisms of and strategies for overcoming resistance to anti-vascular endothelial growth factor therapy in non-small cell lung cancer.
Huang Y; Carbone DP
Biochim Biophys Acta; 2015 Apr; 1855(2):193-201. PubMed ID: 25598052
[TBL] [Abstract][Full Text] [Related]
48. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Haines IE
N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
[No Abstract] [Full Text] [Related]
49. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Cremolini C; Loupakis F; Falcone A
N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
[No Abstract] [Full Text] [Related]
50. Predictive tissue biomarkers for bevacizumab-containing therapy in metastatic colorectal cancer: an update.
Marien KM; Croons V; Martinet W; De Loof H; Ung C; Waelput W; Scherer SJ; Kockx MM; De Meyer GR
Expert Rev Mol Diagn; 2015 Mar; 15(3):399-414. PubMed ID: 25585649
[TBL] [Abstract][Full Text] [Related]
51. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
[TBL] [Abstract][Full Text] [Related]
52. Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.
Jary M; Vernerey D; Lecomte T; Dobi E; Ghiringhelli F; Monnien F; Godet Y; Kim S; Bouché O; Fratte S; Gonçalves A; Leger J; Queiroz L; Adotevi O; Bonnetain F; Borg C
Cancer Epidemiol Biomarkers Prev; 2015 Mar; 24(3):603-12. PubMed ID: 25583947
[TBL] [Abstract][Full Text] [Related]
53. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer.
Augustine TA; Baig M; Sood A; Budagov T; Atzmon G; Mariadason JM; Aparo S; Maitra R; Goel S
Br J Cancer; 2015 Jan; 112(2):313-8. PubMed ID: 25412235
[TBL] [Abstract][Full Text] [Related]
54. Ethical and Professional Challenges Encountered by Laboratory Genetic Counselors.
Groepper D; McCarthy Veach P; LeRoy BS; Bower M
J Genet Couns; 2015 Aug; 24(4):580-96. PubMed ID: 25398381
[TBL] [Abstract][Full Text] [Related]
55. Clinical Management of Pediatric Genomic Testing.
Holm IA
Curr Genet Med Rep; 2014 Dec; 2(4):212-215. PubMed ID: 25396100
[TBL] [Abstract][Full Text] [Related]
56. Population-based genetic risk prediction and stratification for ovarian cancer: views from women at high risk.
Rahman B; Meisel SF; Fraser L; Side L; Gessler S; Wardle J; Lanceley A
Fam Cancer; 2015 Mar; 14(1):135-44. PubMed ID: 25391615
[TBL] [Abstract][Full Text] [Related]
57. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients.
Lee KW; Lee SS; Kim SB; Sohn BH; Lee HS; Jang HJ; Park YY; Kopetz S; Kim SS; Oh SC; Lee JS
Clin Cancer Res; 2015 Jan; 21(2):357-64. PubMed ID: 25388162
[TBL] [Abstract][Full Text] [Related]
58. Overcoming the reimbursement barriers for clinical sequencing.
Deverka PA; Kaufman D; McGuire AL
JAMA; 2014 Nov; 312(18):1857-8. PubMed ID: 25387182
[No Abstract] [Full Text] [Related]
59. The clinical impact of 21-gene recurrence score on treatment decisions for patients with hormone receptor-positive early breast cancer in Korea.
Lee MH; Han W; Lee JE; Kim KS; Park H; Kim J; Bae SY; Shin HJ; Lee JW; Lee ES
Cancer Res Treat; 2015 Apr; 47(2):208-14. PubMed ID: 25381828
[TBL] [Abstract][Full Text] [Related]
60. Some economics on personalized and predictive medicine.
Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
Eur J Health Econ; 2015 Dec; 16(9):985-94. PubMed ID: 25381039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
